

Asymptomatic skin eruption in a 4-year-old male child

AK Douieb,¹ MD, Bayoumi Eassa,² MD

¹Consultant, Department of Dermatology, HPLM, Larache, Morocco

²Department of Dermatology, Farwaniya Hospital, Kuwait

A 4-year-old male child presented to dermatology out-patient clinic with generalized non itchy skin rash on the body of 6 months duration. The condition was slightly worse in hot weather. There was no significant personal or family history. Review of other systems was unremarkable.

Physical examination revealed multiple, brownish-red macules, papules, patches and plaques, without necrosis distributed slightly on the trunk and upper limbs with numerous lesions in lower limbs (Fig. 1 A,B & 2 A,B). The face, palms and soles were relatively spared. There was no excoriation mark. No abnormality was found on the buccal mucosa, teeth and the nails. There was no lymphadenopathy or organomegaly.

His investigation revealed leukocytosis (WBC 15,000/ml) raised ESR (41mm/first hour), and CRP (32mg/l). Hepatic and renal profile, urine analysis, ASOT were normal, chest x-ray and abdominopelvic ultrasonography were normal.

A skin biopsy was performed on the left thigh, which showed mild hyperkeratosis, focal parakeratosis, and mild acanthosis. Lymphocytic exocytosis with mild spongiosis and a few scattered necrotic keratinocytes are seen in the epidermis. Vague vacuolar changes in the basal epidermis are present. Moderately dense Perivascular lymphohistiocytic infiltrate with extravasated red cells are found in the upper reticular dermis (Fig 3 A,B).



Fig. 1A, 1B Few scaly brownish-red lesions on the trunk.




Fig. 2A, 2B Numerous scaly brownish-red lesions in lower limbs.

Correspondence: Dr. AK Douieb, Consultant, Department of Dermatology, HPLM, Larache, Morocco, Email: douieb@menara.ma




Fig. 3A Hyperkeratosis, parakeratosis, acanthosis and superficial perivascular inflammatory infiltrate.




Fig. 3B Hyperkeratosis with focal parakeratosis, acanthosis with exocytosis of lymphocytes and necrotic keratinocytes, vacuolar alteration in basal cell layer. Superficial Perivascular inflammatory infiltrate of lympho-histocytic with extravasations of RBCs.

What is your clinical differential diagnosis?

1. Pityriasis rosea
2. PLC
3. Guttate psoriasis
4. Secondary syphilis

The patient was treated symptomatically with emollients and narrow band UVB for one month with good response.

DISCUSSION

Pityriasis lichenoides chronica (PLC), pityriasis lichenoides et varioliformis acuta (PLEVA), febrile ulceronecrotic Mucha-Habermann disease

are collectively under the group of disease called pityriasis lichenoides (PL). Pityriasis lichenoides was first described by Neisser and Jadassohn in separate reports in 1894.^{1,2} From previous large case series studies,³⁻⁶ it was found that in general population (age >18 years old), the average age of onset was 29-year-old with prevalence, and peaked in the third decade, and there was no strong predisposition in either sex. While in pediatric group, the disease was peaked at 5 and 10 years of age with male predominance. In the febrile ulceronecrotic subtype, the mean age of onset was 30.6 years, and was peaked in the second decade of life, and was also male predominant. It is generally accepted that PLEVA and PLC represented two ends of a continuous spectrum. Features of both acute and chronic lesions may occur in the same person. The descriptive terms acute and chronic are referring to the characteristic of the individual lesions and not the course of the disease. The disease is characterized by recurrent crops of erythematous papules with a centrally adherent mica-like scale that could be easily detached to reveal a shiny, pinkish-brown surface. They occur on the trunk and proximal portions of the extremities. Unlike PLEVA, the papules flatten spontaneously and regress over a period of weeks. It often leaves behind a hyper-hypopigmented macule. Each lesion could last for several weeks, and there are often exacerbations and remissions. The entire course could take several years. In general, those with diffuse distribution of lesions have the shortest average course (11 months), whereas those with peripheral distribution have the longest average course (33 months); and the central distribution one is intermediate. Dark-skinned individuals could primarily present as generalized hypopigmented macules that lack

scale. So a high index of suspicions is needed in interpretation of this disease.⁴

Cutaneous lesion with papulosquamous morphology is commonly found in patients with chronic eczema. However, the lesions in chronic eczema are usually less well-defined and itch is a very common associated symptom. Pityriasis rosea could also present with papulosquamous lesions. However about half of the patients have characteristic herald patches, and female is more commonly affected. Moreover, our patient's skin lesions persisted much long than the usual course in pityriasis rosea, which usually resolved in two months.⁵ Our patient did not volunteer any history of drug exposure before the onset of the skin rash. On the other hand, mucosal or nail involvement, and Wickham's striae on the lesions were expected in lichen planus, but they were absent in our patient. Other differential diagnoses which could not be easily differentiated clinically included guttate psoriasis, pityriasis lichenoides (chronic type), lymphomatoid papulosis (LyP) and secondary syphilis. Gianotti-Crosti disease (popular acrodermatitis of childhood) is an uncommon disease with papulosquamous skin lesions, but in which the lesions tend to be more edematous and were acraly distributed.⁶

Histopathologically, there is a gradual change between PLEVA and PLC. In general, more extensive epidermal involvement with keratinocytes necrosis and dense lymphohistocytic infiltration is found in PLEVA. Both PLEVA and PLC lesions have shown that T cells predominate in both dermal and epidermal inflammatory infiltrates, with CD8+ and CD4+ cells predominate in PLEVA and PLC respectively.^{3,5}

Aetiology of PLC is still unknown. As clustering of cases and familial outbreaks had been observed, so infectious causes such as *Toxoplasma gondii*,⁷ Epstein-Barr virus,⁸ cytomegalovirus, HIV,⁹ and varicella zoster virus had been suggested.¹⁰

Immune-complex mediated vasculitis was first suggested by Black and Marks. But they failed to find any evidence of immunoglobulin or complement deposition in their biopsies.³ Circulating immune complexes, and IgM were found in DEJ or vessel wall in the skin biopsies by Clayton.¹¹ However, these results were not reproducible in other studies.

Wood et al in 1987 postulated that PLEVA and PLC were a primary T-cell lymphoproliferative disorders.¹² And, a subset of infiltrating cells might be the primary target, with epidermal destruction representing a secondary event. The clinical course of the disease might just reflect the host immune response to abnormal cells (neoplastic T cells). In this hypothesis, a small clonal subset of CD8+ cells infiltrate the skin (below the detection threshold of PCR) to give rise to PLC. With more influx of clonal CD8+ cells, the clinical manifestations of PLEVA become evident. At this point, a T-cell clone can be detected. In PLEVA, the host immune response is able to prevent the development of a cutaneous lymphoma; otherwise, the clone may acquire enough genetic alterations to overwhelm the body's immune system. LyP (lymphomatoid papulosis, a relatively more malignant condition) might be the result of a less effective host immune response. Malignant transformation of PLC, though occurred rarely, had been reported. In the literature, the first of such case was published in 1986 by Bleehan and Slater.¹³ Fortson

et al reported the first cutaneous T-cell lymphoma (CTCL) from a child with PLVEA in 1990.¹⁴ Sporadic cases had been reported thereafter with patients' age ranged from eight-months-old to 62-year-old.^{15,16}

Panizzon et al's cases series was the most interesting.¹⁷ Although, all of his patients had PLC and lymphoma, one of them developed Hodgkin disease three years prior to the onset of PLC. And in another patient, lymphoma occurred in the lung. The author argued that PLC might be considered as a paraneoplastic syndrome rather than genuine transformation. All members of the parapsoriasis group have been shown dominant T-cell receptor clonality.¹⁸ And the presence of T-cell clonality might favour the possibility of malignant transformation. Recently, a small cases study consisting of six PLC patients, T-cell clonality (by using primers V γ 1-8/J γ 1-2 and primers V γ 9/J γ 1-2 for T-cell receptor gene) had been detected in three patients. One of them developed CTCL and another had LyP later. However, the significance of this study was doubt as the number of the patients involved was small, and the T-cell receptor gene rearrangement in PLC lesions was not consistent.¹⁹

Treatment of PLC is largely anecdotal or based on uncontrolled case series. Topical corticosteroids are the first line of treatment. However, no studies have specifically compared the efficacy of it with that of either placebo or other treatments. Systemic agents include antibiotics [Tetracycline (2g/day) and erythromycin (600-800 mg/day)], methotrexate (7.5-20 mg/wk), cyclosporine, dapsone, and pentoxifylline had been tried in the order of frequency. PUVA had been used with success in both PLEVA and PLC. The total amount of energy

used varied from 10-370.5 J/cm.² However, recurrences after cessation of therapy or after long periods of remission may occur. promising results had been demonstrated in UVB. Complete remission (BUVB, nUVB) could be reached up to 93.1%. Disease free period was upto 58 and 38 months with BUVB and nUVB respectively. However, longer treatment duration and/or higher energy may be needed in darker skin type individuals.²⁰

In conclusion, current evidences suggested that PLEVA and PLC may represent different stages of evolution of a single entity. Clonality does not seem to correlate with clinical outcome, and only rare cases have been associated with malignant lymphoma. There is no specific treatment for PLEVA and PLC. As PLC is a self-remitting disease, symptomatic treatment is all that is needed in most cases.

REFERENCES

- Neisser A. Zur Frage der lichenoiden Eruptionen. *Verh Dtsch Dermatol Ges* 1894;4:495-9.
- Jadassohn J. Ube rein eingenartiges psoriasiformes und lichenoides Exanthem. *Verh Dtsch Dermatol Ges* 1894; 4:524-9.
- Black MM, Jones EW. "Lymphomatoid" pityriasis lichenoides: a variant with histological features simulating a lymphoma. A clinical and histopathological study of 15 cases with details of long term follow up. *Br J Dermatol* 1972;86:329-47.
- Black MM, Marks R. The inflammatory reaction in pityriasis lichenoides. *Br J Dermatol* 1972;87:533-9.
- Benmaman O, Sanchez JL. Comparative clinicopathological study on pityriasis lichenoides chronica and small plaque parapsoriasis. *Am J Dermatopathol* 1988;10:189-96.
- Willemze R, Scheffer E. Clinical and histologic differentiation between lymphomatoid papulosis and pityriasis lichenoides. *J Am Acad Dermatol* 1985;13:418-28.
- Zlatkov NB, Andreev VC. Toxoplasmosis and pityriasis lichenoides. *Br J Dermatol* 1972;87:114-6.

12. Klein PA, Jones EC, Nelson JL, Clark RA. Infectious causes of pityriasis lichenoides: a case of fulminant infectious mononucleosis. *J Am Acad Dermatol* 2003;49(2 Suppl Case Reports):S151-3.
13. Griffiths JK. Successful long-term use of cyclosporin A in HIV-induced pityriasis lichenoides chronica. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;18:396-7.
14. Boralevi F, Cotto E, Baysse L, Jouvencel AC, Leaute-Labreze C, Taieb A. Is varicella-zoster virus involved in the etiopathogeny of pityriasis lichenoides? *J Invest Dermatol* 2003;121:647-8.
15. Clayton R, Haffenden G, Du Vivier A, Burton J, Mowbray J. Pityriasis lichenoides--an immune complex disease. *Br J Dermatol* 1977;97:629-34.
16. Wood GS, Strickler JG, Abel EA, Deneau DG, Warnke RA. Immunohistology of pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica. Evidence for their interrelationship with lymphomatoid papulosis. *J Am Acad Dermatol* 1987;16(3 Pt 1):559-70.
17. Bleehen SS, Slater DN. Pityriasis lichenoides developing into mycosis fungoides. *Br J Dermatol* 1986;30(suppl):69-70.
18. Fortson JS, Schroeter AL, Esterly NB. Cutaneous T-cell lymphoma (parapsoriasis en plaque). An association with pityriasis lichenoides et varioliformis acuta in young children. *Arch Dermatol* 1990;126:1449-53.
19. Thomson KF, Whittaker SJ, Russell-Jones R, Charles-Holmes R. Childhood cutaneous T-cell lymphoma in association with pityriasis lichenoides chronica. *Br J Dermatol* 1999;141:1146-8.
20. Child FJ, Fraser-Andrews EA, Russell-Jones R. Cutaneous T-cell lymphoma presenting with 'segmental pityriasis lichenoides chronica'. *Clin Exp Dermatol* 1998;23:232.
21. Panizzon RG, Speich R, Dazzi H. Atypical manifestations Chronic papulosquamous skin lesions 33 of pityriasis lichenoides chronica: development into paraneoplasia and non-Hodgkin lymphomas of the skin. *Dermatology* 1992;184:65-9.
22. Zelickson BD, Peters MS, Muller SA, Thibodeau SN, Lust JA, Quam LM, et al. T-cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. *J Am Acad Dermatol* 1991;25(5 Pt 1):787-96.
23. Shieh S, Mikkola DL, Wood GS. Differentiation and clonality of lesional lymphocytes in pityriasis lichenoides chronica. *Arch Dermatol* 2001;137:305-8.
24. Pavlotsky F, Baum S, Barzilai A, Shpiro D, Trau H. UVB therapy of pityriasis lichenoides--our experience with 29 patients. *J Eur Acad Dermatol Venereol* 2006;20:542-7.